What Is Curanex Pharmaceuticals Inc (CURX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Curanex Pharmaceuticals Inc's intrinsic value is estimated at a composite fair value of $0.27. While the stock appears modestly undervalued at $0.22 (implied upside of +26.3%), our analysis suggests a thinner margin of safety across 4 of 7 bullish models. Notably, First Chicago sees the most upside at +177.8% (fair value: $0.60), while ML-RIV is the most conservative at -78.8% ($0.05). The spread between these extremes — +256.6% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CURX?
7 of 13 models are currently active for CURX. Of these, 4 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates CURX's intrinsic value at $0.13, implying -40.2% downside from the current price. See which stocks rank higher →
How Does CURX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, CURX ranks #289 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Curanex Pharmaceuticals Inc's positioning within the Pharmaceutical Preparations segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including licensing and M&A optionality — shape both the opportunity set and risk profile.
Is CURX a Value Trap?
The Value Trap algorithm is not active for CURX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Curanex Pharmaceuticals Inc. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Curanex Pharmaceuticals Inc earns a quality score of 4.4/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +256.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CURX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CURX's 7 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad